Hapoalim Securities Reports On AMRN MARINE Trial

Hapoalim Securities has reported that Amarin Corporation's AMRN 12 week Marine trial was positive.

According to the report, “Amarin plans to submit an NDA for AMR101 to the FDA in 3Q11 for the indication studied in the MARINE trial (very high triglycerides) regardless of the outcome from ANCHOR, which could imply a 3Q12 U.S. approval.”

AMRN has a Buy Rating and $12 PT.

AMRN closed yesterday at $7.07 per share.